Compare GETY & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | TNXP |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.0M | 199.7M |
| IPO Year | 2022 | 2008 |
| Metric | GETY | TNXP |
|---|---|---|
| Price | $0.26 | $11.87 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.78 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 419.2K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $926,244,000.00 | $13,107,000.00 |
| Revenue This Year | $0.37 | $558.11 |
| Revenue Next Year | $1.47 | $38.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.82 | ★ 29.85 |
| 52 Week Low | $0.23 | $9.40 |
| 52 Week High | $3.21 | $29.19 |
| Indicator | GETY | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 44.02 |
| Support Level | $0.23 | $11.98 |
| Resistance Level | $0.29 | $13.18 |
| Average True Range (ATR) | 0.02 | 0.68 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 68.10 | 1.80 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.